Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus

Launched by CAIRO UNIVERSITY · Feb 16, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment option for patients with a skin condition called Lichen Simplex Chronicus (LSC). The researchers want to compare the effectiveness of a specialized laser treatment, known as fractional carbon dioxide laser, against traditional topical corticosteroids (creams or ointments) in helping to relieve symptoms like itching and skin irritation. The trial will involve 60 patients, who will be randomly assigned to different treatment groups. Some will receive the laser treatment along with emollients (moisturizers), while others will receive topical steroids with emollients, and one group will only get the topical steroids.

To be eligible for the trial, participants must have LSC without any other skin conditions and not be using any treatments for at least four weeks prior to joining. Pregnant or breastfeeding women and those with specific health issues that could affect their skin will not be included. Throughout the study, participants will undergo assessments and fill out questionnaires to measure their symptoms and overall well-being. This research aims to find out which treatment is more effective for improving itching and skin health in patients with LSC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with LSC with no underlying dermatological disease, not on topical or systemic treatment for at least 4 weeks prior to study.
• Exclusion Criteria:
• • Pregnant and lactating females.
• • Patients who are diagnosed with any systemic disease that can result in generalized pruritus (e.g. hepatic, renal, uncontrolled diabetes mellitus, thyroid,....etc ) from history.
• • Patients with contraindications to laser e.g., keloidal tendency, post inflammatory hyperpigmentation (PIH).
• • Patients with dermatological disease (e.g. psoriasis, atopic dermatitis, ....etc)